Sumitomo Mitsui Trust Group and Amova Asset Management Co. Report 7.2% Ownership in Arcturus Therapeutics Holdings Inc.

Sumitomo Mitsui Trust Group, Inc. and Amova Asset Management Co., Ltd. have filed a Schedule 13G/A amendment with the SEC, reporting their beneficial ownership of 7.2% of the common stock of Arcturus Therapeutics Holdings Inc. The filing details the ownership structure, indicating that both entities share voting and dispositive power over 1,947,835 shares. The securities are held through their subsidiary, Amova Asset Management Americas, Inc. The filing also includes certifications that the shares were acquired and are held in the ordinary course of business, without the intent to influence control of the issuer. The amendment was signed by senior officials from both Sumitomo Mitsui Trust Group and Amova Asset Management.